Retroviral vectors
AssigneeOxford Biomedica (UK) Limited
InventorsAlan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
Life of this patent
Estimating the term…
Abstract
Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
Claims75
An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, an envelope protein, and optionally one or more RRE-type sequences, wherein the particle lacks all functional lentiviral auxiliary gene products.
An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, an envelope protein and one or more RRE-type sequences, wherein the particle lacks all functional lentiviral auxiliary gene products.
The method of claim wherein the coexpressing is of:
- a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein.
Dependencies are inferred from the claim text.